Indivior declares $8.13/shr special dividend contingent on Supernus merger closing

Indivior Pharmaceuticals, Inc.

Special dividend of $8.13 per share; record date October 30, 2026; payment expected ~November 6, 2026.
Payment contingent on merger closing expected on or about November 2, 2026; no dividend if merger fails.
Supernus stockholders ineligible for dividend on Indivior shares received in merger.
Indivior expects majority of dividend to exceed current/accumulated earnings; treated as return of capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.